CORONA Remedies Limited (NSE:CORONA)
India · Delayed Price · Currency is INR 1,388.30
-70.50 (-4.83%)
At close: Jan 21, 2026
CORONA Remedies Revenue
CORONA Remedies had revenue of 3.61B INR in the quarter ending September 30, 2025, with 19.37% growth. This brings the company's revenue in the last twelve months to 12.99B. In the fiscal year ending March 31, 2025, CORONA Remedies had annual revenue of 11.96B with 17.93% growth.
Revenue (ttm)
12.99B
Revenue Growth
+17.93%
P/S Ratio
6.55
Revenue / Employee
2.89M
Employees
4,508
Market Cap
85.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 11.96B | 1.82B | 17.93% |
| Mar 31, 2024 | 10.14B | 1.30B | 14.75% |
| Mar 31, 2023 | 8.84B | 2.67B | 43.21% |
| Mar 31, 2022 | 6.17B | 411.66M | 7.14% |
| Mar 31, 2021 | 5.76B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 76.18B |
| Granules India | 48.42B |
| Unichem Laboratories | 22.26B |
| FDC Limited | 20.77B |
| Caplin Point Laboratories | 20.42B |
| AstraZeneca Pharma India | 20.06B |
| Sanofi India | 19.33B |
| Viyash Scientific | 16.58B |